BCPC has been the topic of several other reports. Zacks Investment Research cut shares of Balchem from a hold rating to a sell rating in a report on Monday, August 5th. HC Wainwright reaffirmed a buy rating and set a $95.00 target price (down from $110.00) on shares of Balchem in a report on Monday, August 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Balchem presently has a consensus rating of Hold and an average target price of $108.75.
Shares of BCPC stock traded up $0.85 on Thursday, reaching $105.34. The stock had a trading volume of 151,339 shares, compared to its average volume of 116,161. The company has a quick ratio of 2.63, a current ratio of 3.73 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average is $91.67 and its two-hundred day moving average is $94.91. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of 35.00 and a beta of 1.17. Balchem has a 12 month low of $73.16 and a 12 month high of $117.79.
Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Thursday, August 1st. The basic materials company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.08. The firm had revenue of $161.60 million for the quarter, compared to analysts’ expectations of $163.14 million. Balchem had a net margin of 12.27% and a return on equity of 13.87%. The business’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.76 EPS. On average, sell-side analysts forecast that Balchem will post 2.96 earnings per share for the current fiscal year.
In related news, VP Scott C. Mason bought 3,000 shares of the business’s stock in a transaction on Monday, August 5th. The shares were purchased at an average price of $84.74 per share, for a total transaction of $254,220.00. Following the completion of the transaction, the vice president now directly owns 12,524 shares of the company’s stock, valued at approximately $1,061,283.76. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP David F. Ludwig sold 12,750 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $90.00, for a total transaction of $1,147,500.00. Following the completion of the sale, the vice president now owns 21,038 shares in the company, valued at approximately $1,893,420. The disclosure for this sale can be found here. Company insiders own 1.28% of the company’s stock.
A number of institutional investors have recently modified their holdings of BCPC. Nuveen Asset Management LLC acquired a new stake in Balchem in the second quarter valued at approximately $13,608,000. Morgan Stanley boosted its position in Balchem by 895.5% in the second quarter. Morgan Stanley now owns 148,339 shares of the basic materials company’s stock valued at $14,830,000 after buying an additional 133,438 shares in the last quarter. Wasatch Advisors Inc. boosted its position in Balchem by 6.0% in the second quarter. Wasatch Advisors Inc. now owns 1,306,898 shares of the basic materials company’s stock valued at $130,651,000 after buying an additional 74,061 shares in the last quarter. BlackRock Inc. boosted its position in Balchem by 1.0% in the second quarter. BlackRock Inc. now owns 4,712,524 shares of the basic materials company’s stock valued at $471,110,000 after buying an additional 47,908 shares in the last quarter. Finally, Scout Investments Inc. boosted its position in Balchem by 65.2% in the second quarter. Scout Investments Inc. now owns 94,096 shares of the basic materials company’s stock valued at $9,407,000 after buying an additional 37,133 shares in the last quarter. Hedge funds and other institutional investors own 86.43% of the company’s stock.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Recommended Story: Technical Analysis of Stocks and What It Means
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.